C4 Therapeutics Inc (NASDAQ:CCCC) shares, rose in value, with the stock price up by 2.10% to the previous day’s close as strong demand from buyers drove the stock to $2.43.
Actively observing the price movement in the last trading, the stock closed the session at $2.38. Referring to stock’s 52-week performance, its high was $11.48, and the low was $2.21. On the whole, CCCC has fluctuated by -27.68% over the past month.
With the market capitalization of C4 Therapeutics Inc currently standing at about $172.51 million, investors are eagerly awaiting this quarter’s results, scheduled for in April.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 2.95M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that CCCC’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of CCCC currently trading nearly -18.91% and -29.56% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 27.06, while the 7-day volatility ratio is showing 8.93% which for the 30-day chart, stands at 7.21%. Furthermore, C4 Therapeutics Inc (CCCC)’s beta value is 3.00, and its average true range (ATR) is 0.23.
A comparison of C4 Therapeutics Inc (CCCC) with its peers suggests the former has fared considerably weaker in the market. CCCC showed an intraday change of 2.10% in last session, and over the past year, it shrunk by -77.89%%. Additionally, there is a gain of 0.92%% for AstraZeneca PLC ADR (AZN) in last trading while the stock has seen an overall depriciation of 19.44%% over the past year.
Data on historical trading for C4 Therapeutics Inc (NASDAQ:CCCC) indicates that the trading volumes over the past 3 months, they’ve averaged 1.91 million. According to company’s latest data on outstanding shares, there are 70.63 million shares outstanding.
Nearly 20.14% of C4 Therapeutics Inc’s shares belong to company insiders and institutional investors own 83.17% of the company’s shares. The stock has fallen by -32.50% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CCCC stock heading into the next quarter.
